Clinical trials: Malaria (Plasmodium Falciparum)
Malaria
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
This study is a single site, randomized, double-blind, placebo-controlled trial. The trial will assess the safety, tolerability, immunogenicity and vaccine efficacy (VE) of PfSPZ Vaccine in Gabonese children that are naturally…
- Trial name
- NCT03521973
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Gabon
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Falciparum Malaria (Drug Resistant)
Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.
- Trial name
- Artesynib (NCT03697668)
- Testing
- Imatinib, Dihydroartemisinin-piperaquine
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- Nurex S.r.l.
Prophylaxis Against Plasmodium Falciparum Malaria
A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720.
- Trial name
- NCT00284973
- Testing
- Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day
- Trial name
- NCT01524341
- Testing
- KAE609
- Where
- 3 sites in Thailand
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the…
- Trial name
- NCT00371735
- Testing
- chlorproguanil-dapsone-artesunate, chlorproguanil-dapsone
- Where
- 7 sites in Burkina Faso, Ghana and 2 more
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Falciparum Malaria
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
- Trial name
- NCT00894660
- Testing
- Amodiaquine (Test), Amodiaquine (Comparator)
- Where
- Singapore
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Malaria,Falciparum
MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine
First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg
- Trial name
- MSP3CRMV4All (NCT05197751)
- Testing
- MSP3-CRM-Vac4All/ Alhydrogel®
- Where
- Mali
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Vac4All
Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria
The objective of this study is to explore the role of fosmidomycin and piperaquine as non-artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum when administered over three days.
- Trial name
- FOSPIP (NCT02198807)
- Testing
- Fosmidomycin-Piperaquine
- Volunteers
- 100 people
- Sponsor
- Jomaa Pharma GmbH
Malaria, Falciparum
A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™
The Study was designed to evaluate the pharmacokinetics of DHA and PQ in healthy volunteers and to assess the effect of ethnicity (Asian vs Caucasian), gender and body weight on the relative bioavailability of DHA and PQ.
- Trial name
- NCT01222949
- Testing
- Eurartesim
- Where
- 2 sites in Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- sigma-tau i.f.r. S.p.A.
Malaria
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults
The aim of this study is to evaluate the role of azithromycin as a possible combination partner for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium…
- Trial name
- JP011 (NCT01464125)
- Testing
- Fosmidomycin, Azithromycin
- Where
- Thailand
- Volunteers
- 43 people
- Sponsor
- Jomaa Pharma GmbH
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
- Trial name
- NCT00084227
- Testing
- Azithromycin/Chloroquine, Atovaquone/Proguanil
- Volunteers
- 244 people
- Sponsor
- Pfizer
Malaria
Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)
The purpose of this study is to evaluate the clinical performance of the one-step Fyodor Urine Malaria Test (UMT), to determine its accuracy (sensitivity and specificity) for the diagnosis of Plasmodium falciparum malaria in…
- Trial name
- NCT01921413
- Testing
- Urine Malaria Test
- Where
- Nigeria
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Fyodor Biotechnologies Inc
Malaria, Falciparum
A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607
This is an open-label, single-centre, non-randomized study to investigate the pharmacokinetics of GSK3191607, administered as a single intravenous (IV) dose in healthy male subjects.
- Trial name
- NCT02737007
- Testing
- [14C]-GSK3191607
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated…
- Trial name
- NCT00084240
- Testing
- Azithromycin/Chloroquine, Sulfadoxine-Pyrimethamine/Chloroquine
- Volunteers
- 32 people
- Sponsor
- Pfizer
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
This study will be conducted in Siaya County in Nyanza Province, western Kenya. Healthy children aged 5 months through 9 years of age living within approximately 10 km of the study clinic(s) (Siaya County Referral Hospital, or…
- Trial name
- NCT02687373
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Kenya
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Falciparum Malaria
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
The study will determine if artesunate tablet (Pfizer), an antimalarial agent, is pharmaceutically equivalent to Arsuamoon® tablets (Guilin-China).
- Trial name
- NCT00894374
- Testing
- Artesunate (Test), Artesunate (Comparator)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer